As diabetes continues to affect millions across India, the country’s healthcare sector is undergoing a rapid technological shift aimed at improving patient outcomes and disease management. Among the most promising advancements is the growing adoption of continuous glucose monitoring (CGM) devices, a segment set to redefine real-time diabetes care and projected to grow at a compound annual growth rate (CAGR) of approximately 5% between 2025 and 2035, according to GlobalData, a leading data and analytics company.

GlobalData’s latest report, “Insulin Pumps and Continuous Glucose Monitors Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036”, reveals that India accounts to around 5% of the CGM devices market in the Asia-Pacific (APAC) region in 2025.

A notable driver of this progress is the recent breakthrough from the Indian Institute of Technology, Madras (IIT-M). Researchers at IIT-M’s Electronic Materials and Thin Films Lab have developed a cost-effective, minimally invasive CGM device tailored for Indian patients. By combining reusable electronics with a disposable microneedle sensor patch, this device enables accurate real-time glucose tracking while maintaining user comfort and convenience.

Shagufta Hasan, Medical Devices Analyst at GlobalData, comments: “India’s glucose monitoring landscape is shifting from innovation to impact. Affordable, homegrown CGM technologies are breaking long-standing barriers of cost and accessibility. While challenges remain, such advancements mark a defining step toward more inclusive and patient-friendly diabetes management.”

Building on these developments, the market is still with certain hurdles that could limit its full potential—including the affordability of existing CGM systems, integration within digital health ecosystems, and the need for stronger reimbursement and clinical adoption frameworks. Well thought-of solutions like the IIT-M device, which emphasize cost-efficiency, comfort, and reduced device dependency, are expected to drive wider uptake, particularly among rural and price-sensitive populations.

Hasan concludes: “As affordable, user-centric CGM devices gain traction in the local market, they are expected to significantly enhance diabetes care, reduce complications, and ease pressure on healthcare systems. With ongoing innovation and wider accessibility, India is emerging as a key growth driver in the APAC region, strengthening the market’s position as a hub for affordable, technology-led diabetes solutions.”